PMID- 21128234
OWN - NLM
STAT- MEDLINE
DCOM- 20110921
LR  - 20171116
IS  - 1097-0215 (Electronic)
IS  - 0020-7136 (Linking)
VI  - 129
IP  - 6
DP  - 2011 Sep 15
TI  - Ag-bearing liposomes engrafted with peptides that interact with CD11c/CD18 induce 
      potent Ag-specific and antitumor immunity.
PG  - 1391-403
LID - 10.1002/ijc.25810 [doi]
AB  - Dendritic cells (DCs) play key role in eliciting antigen (Ag)-specific immune 
      responses, and crucial to this is the uptake of Ag via surface receptors 
      including the heterodimeric integrin CD11c/CD18. Here we report that 
      CD11c/CD18-interacting peptides can be used as targeting moieties to deliver 
      liposomal Ag to antigen presenting cells (APCs) and elicit Ag-specific and 
      antitumor immunity. Two peptides of sequence related to human ICAM-4 and 
      previously reported to bind CD11c/CD18, and a 12-mer cyclic peptide previously 
      identified by phage display to bind CD11c/CD18, were produced synthetically, and 
      tested for their ability to target liposomal Ag. The three peptides were designed 
      to contain a shorter spacer to reduce steric hindrance, and a His-tag to enable 
      engraftment onto liposomes incorporated with chelator lipid. Our results show 
      that the three peptides, denoted as p17, p18 and p30, promote strong binding of 
      liposomes to CD11c(+) and CD11b(+) cells in vitro and in vivo. Vaccination of 
      mice with Ag-bearing liposomes engrafted with the peptides, particularly p18 and 
      p30, induced Ag-specific T cell priming and antibody production. Importantly, the 
      vaccination of C57BL/6 mice with syngeneic B16-OVA-derived plasma membrane 
      vesicles (PMVs) engrafted with p18 and p30 peptide showed dramatic antitumor 
      responses, inhibiting tumor growth/metastasis in both the lung and subcutaneous 
      tumor models, with a high proportion of the mice apparently being "cured" of 
      their tumors. The engraftment of p18 and p30 peptides onto liposomes and PMVs, 
      thus provides an effective means to target Ags to DCs in vivo, for the 
      development of effective cancer vaccines and immunotherapies.
CI  - Copyright (c) 2010 UICC.
FAU - Faham, Abdus
AU  - Faham A
AD  - Division of Biomedical Science and Biochemistry, Research School of Biology, ANU 
      College of Medicine, Biology and Environment, The Australian National University, 
      Canberra, ACT, Australia.
FAU - Altin, Joseph G
AU  - Altin JG
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110325
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (Antibodies, Neoplasm)
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (CD11 Antigens)
RN  - 0 (CD18 Antigens)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Liposomes)
RN  - 0 (Vaccines, Subunit)
RN  - 9006-59-1 (Ovalbumin)
SB  - IM
MH  - Animals
MH  - Antibodies, Neoplasm/*biosynthesis
MH  - Antigen-Presenting Cells/immunology
MH  - Antigens, Neoplasm/*immunology
MH  - CD11 Antigens/*immunology
MH  - CD18 Antigens/immunology
MH  - Cancer Vaccines/*immunology
MH  - Cell Membrane Structures/metabolism
MH  - Dendritic Cells/immunology
MH  - Female
MH  - Liposomes/*immunology
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Ovalbumin/immunology
MH  - Vaccines, Subunit/*immunology
EDAT- 2010/12/04 06:00
MHDA- 2011/09/22 06:00
CRDT- 2010/12/04 06:00
PHST- 2010/06/15 00:00 [received]
PHST- 2010/11/03 00:00 [accepted]
PHST- 2010/12/04 06:00 [entrez]
PHST- 2010/12/04 06:00 [pubmed]
PHST- 2011/09/22 06:00 [medline]
AID - 10.1002/ijc.25810 [doi]
PST - ppublish
SO  - Int J Cancer. 2011 Sep 15;129(6):1391-403. doi: 10.1002/ijc.25810. Epub 2011 Mar 
      25.